Drugs / human cord blood mononuclear cells

Trials 3 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT01742533 Mar 2012 → Jun 2013 primary ovarian failure Shenzhen Beike Bio-Technology Co., Ltd. Unknown No outcome recorded
Phase 1/2 NCT01443689 Jul 2011 → Mar 2013 Shenzhen Beike Bio-Technology Co., Ltd. Unknown No outcome recorded
Phase 1/2 NCT01343511 Mar 2009 → Jun 2010 autism Shenzhen Beike Bio-Technology Co., Ltd. Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as human cord blood mononuclear cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT01343511
2

NCT01742533

NCT01443689

Known as CBMNCs “This non-randomized, open-label, single center phase I/II trial investigated the safety and efficacy of combined transplantation of human cord blood mononuclear cells (CBMNCs)...” PMID 23978163 Aug 2013
Known as hCB-MNCs “Human umbilical cord mesenchymal stem cells (hUCMSCs) and human cord blood mononuclear cells (hCBMNCs) have been shown to have the ability to modulate the immune response and...” NCT01443689
1

“Human umbilical cord mesenchymal stem cells (hUC-MSCs) and human cord blood mononuclear cells (hCB-MNCs) have been shown to have the ability to modulate the immune response and...” NCT01343511

Modality Cell therapy “Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism.” PMID 23978163 Aug 2013
Route Intrathecal “Transplantations included four stem cell infusions through intravenous and intrathecal injections once a week.” PMID 23978163 Aug 2013
Route Intravenous “Transplantations included four stem cell infusions through intravenous and intrathecal injections once a week.” PMID 23978163 Aug 2013